
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Encequidar
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
Details : HHP and Hanmi Pharm will grant Gilead exclusive global rights to encequidar, a first-in-class P-glycoprotein inhibitor, within the field of virology.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 29, 2025
Lead Product(s) : Encequidar
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
